Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA Spells Out Tasks For 2009

This article was originally published in PharmAsia News

Executive Summary

China's State FDA will concentrate on improving the regulation of standards and supervision of food and drugs in 2009, with the aim of raising standards for all drugs marketed within five years. The agency will speed up its action plan by strengthening international cooperation on formulating standards; revising or raising the quality level of 2,000 drugs; and revising the 2010 Chinese Pharmacopoeia edition. In addition, SFDA will finish the revision of Regulations for the Supervision and Administration of Medical Devices; conduct research on revising the Drug Administration Law and Regulations for the Hygiene Supervision on Cosmetics; implement Provisions for Drug Registration and its complementary documents; as well as continuously formulate and standardize technical appraisal guidelines for drugs and medical devices. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069859

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel